Gene Therapy Strategies for Alzheimer's Disease: An Overview
- PMID: 26838997
- DOI: 10.1089/hum.2016.017
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Abstract
Key neuropathological hallmarks of Alzheimer's disease (AD) are extracellular amyloid plaques and intracellular accumulation of hyperphosphorylated Tau protein. The mechanisms underlying these neuropathological changes remain unclear. So far, research on AD therapy has had limited success in terms of symptomatic treatments although it has also had several failures for disease-modifying drugs. Gene transfer strategies to the brain have contributed to evaluate in animal models many interesting tracks, some of which should deserve clinical applications in AD patients in the future.
Similar articles
-
A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice.Acta Biomater. 2017 Feb;49:388-401. doi: 10.1016/j.actbio.2016.11.029. Epub 2016 Nov 11. Acta Biomater. 2017. PMID: 27845275
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
Transcriptional and post-transcriptional regulation of β-secretase.IUBMB Life. 2012 Dec;64(12):943-50. doi: 10.1002/iub.1099. IUBMB Life. 2012. PMID: 23180460 Review.
-
[Pathogenesis of Alzheimer's disease: molecular and cellular mechanisms].Rev Med Liege. 2007 Apr;62(4):209-16. Rev Med Liege. 2007. PMID: 17566391 Review. French.
-
The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.Anat Rec (Hoboken). 2011 Aug;294(8):1307-18. doi: 10.1002/ar.21425. Epub 2011 Jun 29. Anat Rec (Hoboken). 2011. PMID: 21717585 Review.
Cited by
-
Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.Neurobiol Dis. 2023 Oct 1;186:106285. doi: 10.1016/j.nbd.2023.106285. Epub 2023 Sep 9. Neurobiol Dis. 2023. PMID: 37690676 Free PMC article.
-
Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimer's disease by evaluating protein interactions through molecular docking and dynamic simulations.Neurol Sci. 2018 Aug;39(8):1361-1374. doi: 10.1007/s10072-018-3430-2. Epub 2018 May 22. Neurol Sci. 2018. PMID: 29789968
-
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer's Disease.Cells. 2020 Nov 20;9(11):2513. doi: 10.3390/cells9112513. Cells. 2020. PMID: 33233678 Free PMC article. Review.
-
Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration.Nat Rev Neurosci. 2020 Feb;21(2):93-102. doi: 10.1038/s41583-019-0255-9. Epub 2020 Jan 8. Nat Rev Neurosci. 2020. PMID: 31913356 Review.
-
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5. Neurobiol Dis. 2019. PMID: 30849508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical